[Fluticasone propionate in treatment of seasonal allergic rhinitis--open multicenter study].
Eighty five patients with seasonal allergic rhinitis, currently symptomatic, were treated with fluticasone proportionate nasal spray (Flixonase) in open, multicentre efficacy and safety study. The drug studied statistically significant decrease all but one (conjunctivitis) symptoms of the disease in the first week of treatment in the patient's and doctor's assessment. The full effect of treatment was revealed in the second week. There was significant protective effect observed during two weeks after the cessation of treatment. Adverse events were mild and occurred in two cases, due to disease itself rather, than the drug tested.
Kokot
M
M
Dział Medyczny, Glaxo Welicome Polska Sp. z o.o.w Warszawie.
Barliński
J
J
D000281:Administration, Intranasal; D000328:Adult; D000730:Androstadienes / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D005260:Female; D000068298:Fluticasone; D006801:Humans; D008297:Male; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D016896:Treatment Outcome
D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000068298:Fluticasone
Propionian flutikazonu w leczeniu sezonowego alergicznego niezytu nosa--otwarta próba wieloośrodkowa.